The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2022 | Considerations for transplant in myelofibrosis
Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clínico Universitario Valencia, Valencia, outlines the most important considerations for hematopoietic stem cell transplantation (HSCT) in myelofibrosis (MF). To begin with, it is crucial to select the right patients for transplantation, namely patients with high-risk disease and patients with an expected survival of less than five years. Subsequently, it is important to predict transplantation outcomes and define the optimal timing for transplant before discussing the benefits and risks of this procedure with the patient. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.
